Low affinity immunoglobulin epsilon Fc receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Low affinity immunoglobulin epsilon Fc receptor shows clinical signal disease relevance led by chronic lymphocytic leukemia. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P06734. Start with chronic lymphocytic leukemia, then reuse UniProt P06734 as the stable protein anchor across project notes and exports.
Start with chronic lymphocytic leukemia, then reuse UniProt P06734 as the stable protein anchor across project notes and exports.
Low affinity immunoglobulin epsilon Fc receptor shows clinical signal disease relevance led by chronic lymphocytic leukemia. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include LUMILIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLow affinity immunoglobulin epsilon Fc receptor
Review this target as Low affinity immunoglobulin epsilon Fc receptor, mapped to UniProt P06734. Sequence length is 321 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Low affinity immunoglobulin epsilon Fc receptor as ChEMBL target CHEMBL2940, mapped to UniProt P06734. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Low affinity immunoglobulin epsilon Fc receptor is the right protein anchor across sources, using UniProt P06734 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Low affinity immunoglobulin epsilon Fc receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P06734 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Low affinity immunoglobulin epsilon Fc receptor |
| UniProt Accession | P06734 |
| Component Type | Protein |
| Sequence Length | 321 aa |
Low affinity immunoglobulin epsilon Fc receptor
Review this target as Low affinity immunoglobulin epsilon Fc receptor, mapped to UniProt P06734. Sequence length is 321 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Low affinity immunoglobulin epsilon Fc receptor shows clinical signal disease relevance led by chronic lymphocytic leukemia. 2 more disease programs remain visible in the same review block.
Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include LUMILIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL115348 | 7.92 | IC50 | 12.0 | Preclinical |
| CHEMBL118054 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL324564 | 7.8 | IC50 | 16.0 | Preclinical |
| CHEMBL115326 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL322050 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL323228 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL432583 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL115211 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL424251 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL114427 | 7.4 | IC50 | 40.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 12 | 36 | 6.6 |
| single protein format | 1 | 16 | 6.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 10 | 5.8 |